Selected research
Industry Research
Multiplex Immunofluorescence (mIF) Technology Industry Research Report 2026
Market perspective
The global Multiplex Immunofluorescence (mIF) Technology market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Multiplex Immunofluorescence (mIF) Technology market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Multiplex Immunofluorescence (mIF) Technology market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Multiplex Immunofluorescence (mIF) Technology market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Multiplex Immunofluorescence (mIF) Technology include Eureka Biotech, ICON plc, Discovery Life Sciences, Precision Medicine Group, Terry Technologies, MGI Tech, panovue, Biospective and iCuraDx, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Multiplex Immunofluorescence (mIF) Technology market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Multiplex Immunofluorescence (mIF) Technology.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Multiplex Immunofluorescence (mIF) Technology Market by Company
Eureka Biotech
ICON plc
Discovery Life Sciences
Precision Medicine Group
Terry Technologies
MGI Tech
panovue
Biospective
iCuraDx
Yucebio
Flagship Biosciences
Lanterne Dx (LDX)
Crown Bioscience
Multiplex Immunofluorescence (mIF) Technology Segment by Type
Direct Labeling mIF Technology
TSA-based Amplification mIF Technology
Dual-amplification mIF Technology
Multiplex Immunofluorescence (mIF) Technology Segment by Application
Tumor Immunology Research
Clinical Pathological Diagnosis
Immune Microenvironment Profiling
Other
Multiplex Immunofluorescence (mIF) Technology Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiplex Immunofluorescence (mIF) Technology market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Multiplex Immunofluorescence (mIF) Technology and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiplex Immunofluorescence (mIF) Technology.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Multiplex Immunofluorescence (mIF) Technology companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Direct Labeling mIF Technology
- TSA-based Amplification mIF Technology
- Dual-amplification mIF Technology
Applications
- Tumor Immunology Research
- Clinical Pathological Diagnosis
- Immune Microenvironment Profiling
- Other
Companies covered
- Eureka Biotech
- ICON plc
- Discovery Life Sciences
- Precision Medicine Group
- Terry Technologies
- MGI Tech
- panovue
- Biospective
- iCuraDx
- Yucebio
- Flagship Biosciences
- Lanterne Dx (LDX)
- Crown Bioscience
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Multiplex Immunofluorescence (mIF) Technology by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Direct Labeling mIF Technology
- 2.2.3 TSA-based Amplification mIF Technology
- 2.2.4 Dual-amplification mIF Technology
- 2.3 Multiplex Immunofluorescence (mIF) Technology by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Tumor Immunology Research
- 2.3.3 Clinical Pathological Diagnosis
- 2.3.4 Immune Microenvironment Profiling
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Multiplex Immunofluorescence (mIF) Technology Breakdown Data by Type
- 3.1 Global Multiplex Immunofluorescence (mIF) Technology Historic Market Size by Type (2021-2026)
- 3.2 Global Multiplex Immunofluorescence (mIF) Technology Forecasted Market Size by Type (2027-2032)
4 Multiplex Immunofluorescence (mIF) Technology Breakdown Data by Application
- 4.1 Global Multiplex Immunofluorescence (mIF) Technology Historic Market Size by Application (2021-2026)
- 4.2 Global Multiplex Immunofluorescence (mIF) Technology Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Multiplex Immunofluorescence (mIF) Technology Market Perspective (2021-2032)
- 5.2 Global Multiplex Immunofluorescence (mIF) Technology Growth Trends by Region
- 5.2.1 Global Multiplex Immunofluorescence (mIF) Technology Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Multiplex Immunofluorescence (mIF) Technology Historic Market Size by Region (2021-2026)
- 5.2.3 Multiplex Immunofluorescence (mIF) Technology Forecasted Market Size by Region (2027-2032)
- 5.3 Multiplex Immunofluorescence (mIF) Technology Market Dynamics
- 5.3.1 Multiplex Immunofluorescence (mIF) Technology Industry Trends
- 5.3.2 Multiplex Immunofluorescence (mIF) Technology Market Drivers
- 5.3.3 Multiplex Immunofluorescence (mIF) Technology Market Challenges
- 5.3.4 Multiplex Immunofluorescence (mIF) Technology Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Multiplex Immunofluorescence (mIF) Technology Players by Revenue
- 6.1.1 Global Top Multiplex Immunofluorescence (mIF) Technology Players by Revenue (2021-2026)
- 6.1.2 Global Multiplex Immunofluorescence (mIF) Technology Revenue Market Share by Players (2021-2026)
- 6.2 Global Multiplex Immunofluorescence (mIF) Technology Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Multiplex Immunofluorescence (mIF) Technology Head Office and Area Served
- 6.4 Global Multiplex Immunofluorescence (mIF) Technology Players, Product Type & Application
- 6.5 Global Multiplex Immunofluorescence (mIF) Technology Manufacturers Established Date
- 6.6 Global Multiplex Immunofluorescence (mIF) Technology Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Multiplex Immunofluorescence (mIF) Technology Market Size (2021-2032)
- 7.2 North America Multiplex Immunofluorescence (mIF) Technology Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Multiplex Immunofluorescence (mIF) Technology Market Size by Country (2021-2026)
- 7.4 North America Multiplex Immunofluorescence (mIF) Technology Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Multiplex Immunofluorescence (mIF) Technology Market Size (2021-2032)
- 8.2 Europe Multiplex Immunofluorescence (mIF) Technology Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Multiplex Immunofluorescence (mIF) Technology Market Size by Country (2021-2026)
- 8.4 Europe Multiplex Immunofluorescence (mIF) Technology Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Multiplex Immunofluorescence (mIF) Technology Market Size (2021-2032)
- 9.2 Asia-Pacific Multiplex Immunofluorescence (mIF) Technology Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Multiplex Immunofluorescence (mIF) Technology Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Multiplex Immunofluorescence (mIF) Technology Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Multiplex Immunofluorescence (mIF) Technology Market Size (2021-2032)
- 10.2 South America Multiplex Immunofluorescence (mIF) Technology Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Multiplex Immunofluorescence (mIF) Technology Market Size by Country (2021-2026)
- 10.4 South America Multiplex Immunofluorescence (mIF) Technology Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Multiplex Immunofluorescence (mIF) Technology Market Size (2021-2032)
- 11.2 Middle East & Africa Multiplex Immunofluorescence (mIF) Technology Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Multiplex Immunofluorescence (mIF) Technology Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Multiplex Immunofluorescence (mIF) Technology Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Eureka Biotech
- 12.1.1 Eureka Biotech Company Information
- 12.1.2 Eureka Biotech Business Overview
- 12.1.3 Eureka Biotech Revenue in Multiplex Immunofluorescence (mIF) Technology Business (2021-2026)
- 12.1.4 Eureka Biotech Multiplex Immunofluorescence (mIF) Technology Product Portfolio
- 12.1.5 Eureka Biotech Recent Developments
- 12.2 ICON plc
- 12.2.1 ICON plc Company Information
- 12.2.2 ICON plc Business Overview
- 12.2.3 ICON plc Revenue in Multiplex Immunofluorescence (mIF) Technology Business (2021-2026)
- 12.2.4 ICON plc Multiplex Immunofluorescence (mIF) Technology Product Portfolio
- 12.2.5 ICON plc Recent Developments
- 12.3 Discovery Life Sciences
- 12.3.1 Discovery Life Sciences Company Information
- 12.3.2 Discovery Life Sciences Business Overview
- 12.3.3 Discovery Life Sciences Revenue in Multiplex Immunofluorescence (mIF) Technology Business (2021-2026)
- 12.3.4 Discovery Life Sciences Multiplex Immunofluorescence (mIF) Technology Product Portfolio
- 12.3.5 Discovery Life Sciences Recent Developments
- 12.4 Precision Medicine Group
- 12.4.1 Precision Medicine Group Company Information
- 12.4.2 Precision Medicine Group Business Overview
- 12.4.3 Precision Medicine Group Revenue in Multiplex Immunofluorescence (mIF) Technology Business (2021-2026)
- 12.4.4 Precision Medicine Group Multiplex Immunofluorescence (mIF) Technology Product Portfolio
- 12.4.5 Precision Medicine Group Recent Developments
- 12.5 Terry Technologies
- 12.5.1 Terry Technologies Company Information
- 12.5.2 Terry Technologies Business Overview
- 12.5.3 Terry Technologies Revenue in Multiplex Immunofluorescence (mIF) Technology Business (2021-2026)
- 12.5.4 Terry Technologies Multiplex Immunofluorescence (mIF) Technology Product Portfolio
- 12.5.5 Terry Technologies Recent Developments
- 12.6 MGI Tech
- 12.6.1 MGI Tech Company Information
- 12.6.2 MGI Tech Business Overview
- 12.6.3 MGI Tech Revenue in Multiplex Immunofluorescence (mIF) Technology Business (2021-2026)
- 12.6.4 MGI Tech Multiplex Immunofluorescence (mIF) Technology Product Portfolio
- 12.6.5 MGI Tech Recent Developments
- 12.7 panovue
- 12.7.1 panovue Company Information
- 12.7.2 panovue Business Overview
- 12.7.3 panovue Revenue in Multiplex Immunofluorescence (mIF) Technology Business (2021-2026)
- 12.7.4 panovue Multiplex Immunofluorescence (mIF) Technology Product Portfolio
- 12.7.5 panovue Recent Developments
- 12.8 Biospective
- 12.8.1 Biospective Company Information
- 12.8.2 Biospective Business Overview
- 12.8.3 Biospective Revenue in Multiplex Immunofluorescence (mIF) Technology Business (2021-2026)
- 12.8.4 Biospective Multiplex Immunofluorescence (mIF) Technology Product Portfolio
- 12.8.5 Biospective Recent Developments
- 12.9 iCuraDx
- 12.9.1 iCuraDx Company Information
- 12.9.2 iCuraDx Business Overview
- 12.9.3 iCuraDx Revenue in Multiplex Immunofluorescence (mIF) Technology Business (2021-2026)
- 12.9.4 iCuraDx Multiplex Immunofluorescence (mIF) Technology Product Portfolio
- 12.9.5 iCuraDx Recent Developments
- 12.10 Yucebio
- 12.10.1 Yucebio Company Information
- 12.10.2 Yucebio Business Overview
- 12.10.3 Yucebio Revenue in Multiplex Immunofluorescence (mIF) Technology Business (2021-2026)
- 12.10.4 Yucebio Multiplex Immunofluorescence (mIF) Technology Product Portfolio
- 12.10.5 Yucebio Recent Developments
- 12.11 Flagship Biosciences
- 12.11.1 Flagship Biosciences Company Information
- 12.11.2 Flagship Biosciences Business Overview
- 12.11.3 Flagship Biosciences Revenue in Multiplex Immunofluorescence (mIF) Technology Business (2021-2026)
- 12.11.4 Flagship Biosciences Multiplex Immunofluorescence (mIF) Technology Product Portfolio
- 12.11.5 Flagship Biosciences Recent Developments
- 12.12 Lanterne Dx (LDX)
- 12.12.1 Lanterne Dx (LDX) Company Information
- 12.12.2 Lanterne Dx (LDX) Business Overview
- 12.12.3 Lanterne Dx (LDX) Revenue in Multiplex Immunofluorescence (mIF) Technology Business (2021-2026)
- 12.12.4 Lanterne Dx (LDX) Multiplex Immunofluorescence (mIF) Technology Product Portfolio
- 12.12.5 Lanterne Dx (LDX) Recent Developments
- 12.13 Crown Bioscience
- 12.13.1 Crown Bioscience Company Information
- 12.13.2 Crown Bioscience Business Overview
- 12.13.3 Crown Bioscience Revenue in Multiplex Immunofluorescence (mIF) Technology Business (2021-2026)
- 12.13.4 Crown Bioscience Multiplex Immunofluorescence (mIF) Technology Product Portfolio
- 12.13.5 Crown Bioscience Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst